PHCCC is a research drug which acts as a glutamate receptor ligand particularly being a positive allosteric modulator at the mGluR4 subtype as well as an agonist at mGluR6. It has anxiolytic effects in animal studies. PHCCC and similar drugs have been suggested as novel treatments for Parkinson’s disease.
This page contains content from the copyrighted Wikipedia article "PHCCC"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
